# FDA Blocked Publication of Vaccine Safety Research

The Food and Drug Administration blocked the release of research examining the safety profiles of Covid and shingles vaccines, according to reporting from the New York Times. The agency's own scientists and contracted data analysts had reviewed millions of patient medical records to conduct these studies.

The research was completed but never published. The FDA withdrew the studies before they could reach peer review or public release, raising questions about scientific transparency and how health agencies handle vaccine safety data.

The timing matters. Both Covid and shingles vaccines represent major public health interventions. The Covid vaccines rolled out under emergency authorization starting in late 2020. The shingles vaccine, Shingrix, received full FDA approval in 2017 but expanded dramatically in use afterward. Independent safety monitoring builds public confidence in vaccination programs, particularly when conducted by the agencies responsible for approving these treatments.

The FDA maintains a surveillance system called the Vaccine Adverse Event Reporting System, or VAERS, which tracks reported side effects. However, VAERS relies on voluntary reporting and captures a fraction of actual adverse events. Large-scale studies examining actual patient records in insurance databases or electronic health systems provide more complete safety data.

The decision to block publication runs counter to standard scientific practice. Completed vaccine safety research typically undergoes peer review before publication, allowing other experts to scrutinize methods and conclusions. This transparency strengthens public trust in health agencies and helps clinicians make informed decisions.

Several vaccine safety experts have noted that withholding completed research creates skepticism rather than preventing it. When studies disappear without explanation, people naturally wonder what findings justified suppression. Publication allows scientists to debate methodology and results openly.

The FDA has not publicly explained why these studies were pulled. Understanding the agency's rationale matters for evaluating what happened and whether similar decisions might affect other research. Public health agencies depend on transparent communication about vaccine safety to maintain